News und Analysen

In the realm of investing, market capitalization is a good but not perfect way to gauge the success of a business. Sure, sometimes companies are overvalued. But a company's market value can at least

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Investors continue to sour on fintech giant PayPal (NASDAQ: PYPL), and its stock is down 12% this year despite sustained growth and progress in cost cutting.

At the same time, competitor Block

Not long ago, financial technology, or fintech, was the hottest investment thesis on Wall Street. While many trends have come and gone since then, the prevalence of digital payments has stuck

Shares of Apple (NASDAQ: AAPL) have pulled back significantly since the company's earnings report earlier this month. As of this writing, the stock has fallen a total of about 7% since the quarterly

The debut of OpenAI's ChatGPT last November captivated tech enthusiasts and forced the public to rethink what was possible with artificial intelligence (AI). Since then, countless businesses have

In the world of artificial intelligence (AI) hardware, Nvidia (NASDAQ: NVDA) reigns supreme. However, another competitor also has a solid AI product lineup: AMD (NASDAQ: AMD). While AMD's technology

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

Last month was a good one for the broad market, but a great one for select stocks. Whereas the S&P 500 advanced another 3.1% in July, a handful of the S&P 500's constituents dished out double-digit

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

Microsoft (NASDAQ: MSFT) stock has been under pressure since the technology giant released its fiscal 2023 fourth-quarter results (for the quarter ended June 30) on July 25, driven mainly by

Earnings season is here, with countless stocks on the move. The tech industry, in particular, is experiencing a lot of fluctuation as macroeconomic headwinds continue to burden many companies. 

Open Lending (NASDAQ: LPRO) was in freefall on Wednesday, falling as much as 35.6% during the trading day. By 3:15 p.m. ET it had gained back some of its losses and was down 22.6% on the day. Year

If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals

GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to

There are many good reasons for investors to be attracted to Adobe's (NASDAQ: ADBE) business right now. Few other software specialists can claim anything approaching its market dominance in key

Apple (NASDAQ: AAPL) shares have skyrocketed roughly 140,000% since the company first went public in 1980. The tech giant has achieved the highest market cap in the world, surpassing $3 trillion

Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli

Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300

Nucor (NYSE: NUE) is an industry-leading steelmaker, utilizing a vertically integrated business model. That means it has scrap-metal operations, makes commodity steel, and uses its own steel to

Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it

Share prices of Apple (NASDAQ: AAPL) slipped nearly 5% after the company released fiscal 2023 third-quarter results (for the three months ended July 1) on Aug. 3. Apparently, investors pressed the